Immunogenicity of a DNA vaccine candidate for COVID-19.
Smith TRF., Patel A., Ramos S., Elwood D., Zhu X., Yan J., Gary EN., Walker SN., Schultheis K., Purwar M., Xu Z., Walters J., Bhojnagarwala P., Yang M., Chokkalingam N., Pezzoli P., Parzych E., Reuschel EL., Doan A., Tursi N., Vasquez M., Choi J., Tello-Ruiz E., Maricic I., Bah MA., Wu Y., Amante D., Park DH., Dia Y., Ali AR., Zaidi FI., Generotti A., Kim KY., Herring TA., Reeder S., Andrade VM., Buttigieg K., Zhao G., Wu J-M., Li D., Bao L., Liu J., Deng W., Qin C., Brown AS., Khoshnejad M., Wang N., Chu J., Wrapp D., McLellan JS., Muthumani K., Wang B., Carroll MW., Kim JJ., Boyer J., Kulp DW., Humeau LMPF., Weiner DB., Broderick KE.
The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.